Negative FDA Review of Acorda's MS Drug Drops Stock Price

Full story: Pharmaceutical Processing

A panel of FDA advisers is scheduled to meet next week to vote on Acorda's Fampridine-SR, which is designed to improve patients' ability to walk.

Read Comments

Comments

Showing posts 1 - 1 of1

Sacramento Copaxone User

Sacramento, CA

On October 14, however, an FDA panel voted 10 to 2 to approve Fampridine to improve walking speed. I have been using slow-release 4-aminopyridine, the chemical name for Fampridine SR, for over 1.5 years with no adverse side effects and a decided improvement in my walking ability. I hope the full FDA follows the October 14 panel's lead.

	Sign up to receive email when someone responds
	(registration is not required)

Showing posts 1 - 1 of1

Type in your comments to post to the forum

Name
(appears on your post)

Comments

Type the numbers you see in the image on the right:

Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Other Recent Multiple Sclerosis Discussions

Topic	Updated	Last By	Comments
Dr. Paolo Zamboni at his research lab at the Un...	4 hr	Toni Dayton...	29
Dr. Paolo Zamboni at his research lab at the Un...	Fri	Val	74
W5 investigates intriguing new theory about MS	Dec 22	Ann	13
Dr. Paolo Zamboni at his research lab at the Un...	Dec 21	wed from sau...	194
Do you bruise badly since MS? (Jul '08)	Dec 20	Carrie	20
Impaired small-world efficiency in structural c...	Dec 12	Stephany McD...	1
Dr. Paolo Zamboni Canadian Research 2 Update	Dec 12	Tara-Lynn	1